Envision the Future and Take on the Power of Computing with GIGABYTE at COMPUTEX 2022
19.5.2022 17:29:00 EEST | Business Wire | Press release
GIGABYTE, a world leader in computer technology, will be presenting “Power of Computing” as its theme of the year, and exhibiting its leading products and solutions designed for various industries and fields in the upcoming COMPUTEX Taipei.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005640/en/
Envision the Future and Take on the Power of Computing with GIGABYTE at COMPUTEX 2022
GIGABYTE has curated its presentation around the theme “Power of Computing” to demonstrate that, everything from the cloud to the edge, from team collaboration to individual creation, from business applications to personal use, computing done by servers in data centers to process massive data and embedded systems in IoT and personal computers to render real-time information is the key behind groundbreaking innovations that appear in the fields of AI, cloud deployment, smart technologies, and digital content creation, etc.
Data Center is an integral part of making technological breakthroughs. GIGABYTE is a trusted pioneer in developing new server products for developers, and worked on software integrations to provide product solutions that are in line with the future of the digital age. GIGABYTE also works closely with vendors in early stages of HPC server platform development, so that system integration and optimization of SmartNICs and GPGPUs allow for heterogeneous architecture in servers to provide application-specific computing acceleration the higher computation and efficiency. In addition to supporting x86 applications using AMD and Intel processors, GIGABYTE also offers the choice of ARM servers that provide consistent data processing and encoding from the user’s terminal to edge, which not only enhances an agile response but also accelerates the development of innovations in the edge computing-piloted 5G era.
GIGABYTE is dedicated to use computing performance to accelerate innovation and advance quality of life, and has devoted effort into development of various cooling methods that includes launching products with direct liquid cooling and immersion cooling technologies to reduce the environmental impact of increased heat generated by data centers.
In the new digital age driven by AI-enabled applications, GIGABYTE has coupled its servers with MyelinTe's MLSteam platform to cluster all computing servers, storage and management nodes to facilitate resource allocation, monitoring and management, and effectively maximize resource utilization. GIGABYTE further expands its hardware experience and expertise by releasing embedded computers into everyday applications such as the fields of self-driving cars and the Internet of Vehicles. GIGABYTE's ADCU series can process massive data and make vehicle-control decisions on a real-time basis; and T-BOX can handle data and mutual communications between on-road vehicles, which is an ideal solution suitable for commercial fleet management.
Computing powers the engine for technological progression, not only to enabling successes in businesses, but also providing exhilarating personal experiences. GIGABYTE exhibits an NVIDIA Omniverse™ virtual collaboration scenario with a host-client setup using its high-performance W771-Z00 workstation and visual-spectacle BRIX mini PC; an awe-inspiring gaming showcase of flagship gaming solutions powered by Intel 12th gen processors, iF Design award-winning motherboards and monitor, and AMD Socket AM5 motherboards with advanced design and extensive features of PCIe 5.0 graphics slot and m.2 Gen5 interface; and GIGABYTE's creator/gaming laptops provide high performance with premium visual experience, with its newest flagship gaming laptop featuring the 12th Gen Intel® Core™ i9 HX series processor, offer a glimpse at the Metaverse potential.
From May 24th to 27th, GIGABYTE is primed, with an array of product solutions and applications, and ready to exhibit its hardware expertise and technology know-how, which possess the computing performance to accelerate technology innovations and uphold its vision to “Upgrade Your Life”
GIGABYTE @ COMPUTEX 2022 - https://gbte.tech/CX22
More About GIGABYTE enterprise: https://www.gigabyte.com/enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005640/en/
Contact information
Media: Michael Pao brand@gigabyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom